446 related articles for article (PubMed ID: 28992762)
1. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
2. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
3. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
[TBL] [Abstract][Full Text] [Related]
4. Characterization of acute myeloid leukemia based on levels of global hydroxymethylation.
Kroeze LI; Aslanyan MG; van Rooij A; Koorenhof-Scheele TN; Massop M; Carell T; Boezeman JB; Marie JP; Halkes CJ; de Witte T; Huls G; Suciu S; Wevers RA; van der Reijden BA; Jansen JH;
Blood; 2014 Aug; 124(7):1110-8. PubMed ID: 24986689
[TBL] [Abstract][Full Text] [Related]
5. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of novel mutations in epigenetic modifiers in AML.
Abdel-Wahab O; Patel J; Levine RL
Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
[TBL] [Abstract][Full Text] [Related]
7. Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia.
Jost E; Lin Q; Weidner CI; Wilop S; Hoffmann M; Walenda T; Schemionek M; Herrmann O; Zenke M; Brümmendorf TH; Koschmieder S; Wagner W
Leukemia; 2014 Jun; 28(6):1227-34. PubMed ID: 24280869
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations.
Šestáková Š; Krejčík Z; Folta A; Cerovská E; Šálek C; Merkerová MD; Pecherková P; Ráčil Z; Mayer J; Cetkovský P; Remešová H
Cancer Biomark; 2019; 25(1):43-51. PubMed ID: 30988238
[TBL] [Abstract][Full Text] [Related]
9. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
[TBL] [Abstract][Full Text] [Related]
10. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
Aslanyan MG; Kroeze LI; Langemeijer SM; Koorenhof-Scheele TN; Massop M; van Hoogen P; Stevens-Linders E; van de Locht LT; Tönnissen E; van der Heijden A; da Silva-Coelho P; Cilloni D; Saglio G; Marie JP; Tang R; Labar B; Amadori S; Muus P; Willemze R; Marijt EW; de Witte T; van der Reijden BA; Suciu S; Jansen JH
Ann Hematol; 2014 Aug; 93(8):1401-12. PubMed ID: 24994606
[TBL] [Abstract][Full Text] [Related]
11. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
[TBL] [Abstract][Full Text] [Related]
12. Clinical Implication of DNMT3A and TET2 Genes Mutations in Cytogenetically Normal Acute Myeloid Leukemia.
Aref S; Sallam N; Abd Elaziz S; Salama O; Al Ashwah S; Ayed M
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4299-4305. PubMed ID: 36580013
[TBL] [Abstract][Full Text] [Related]
13. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.
Chan SM; Majeti R
Int J Hematol; 2013 Dec; 98(6):648-57. PubMed ID: 23949914
[TBL] [Abstract][Full Text] [Related]
14. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.
Abdel-Wahab O; Levine RL
Blood; 2013 May; 121(18):3563-72. PubMed ID: 23640996
[TBL] [Abstract][Full Text] [Related]
15. Lineage restriction analyses in CHIP indicate myeloid bias for
Buscarlet M; Provost S; Zada YF; Bourgoin V; Mollica L; Dubé MP; Busque L
Blood; 2018 Jul; 132(3):277-280. PubMed ID: 29764839
[TBL] [Abstract][Full Text] [Related]
16. TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX; Hollingshead M; Rubinstein L; Nguyen D; Larenjeira ABA; Kinders RJ; Difilippantonio M; Doroshow JH
J Hematol Oncol; 2021 May; 14(1):83. PubMed ID: 34039392
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
18. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.
Sandoval JE; Huang YH; Muise A; Goodell MA; Reich NO
J Biol Chem; 2019 Mar; 294(13):4898-4910. PubMed ID: 30705090
[TBL] [Abstract][Full Text] [Related]
20. TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.
Damm F; Markus B; Thol F; Morgan M; Göhring G; Schlegelberger B; Krauter J; Heuser M; Bernard OA; Ganser A
Genes Chromosomes Cancer; 2014 Oct; 53(10):824-32. PubMed ID: 24898826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
